Trutakna
BLA 761486, held by Vera Therapeutics Inc.. Atacicept-Vymj.
- First approved: Jul 7, 2026
- Review: Priority
- Supplements approved: 0
- Complete response letters: 0
Approvals and New Uses
The original application and every efficacy supplement, newest first| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 7, 2026 | Original applicationNew molecular entity · Priority review | Approved |
Products
1 strengths and forms| Product | Active ingredient | Marketing |
|---|---|---|
| Trutakna150MG/ML · injectable;subcutaneous | Atacicept-Vymj | Rx |
Identifiers
- Application
- BLA 761486
- Drugs@FDA
- Overview at FDA
- Company
- Vera Therapeutics, Inc.
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed weekly; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters